These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30191846)

  • 61. Re: Determinants of BRAF mutations in primary melanomas.
    Purdue MP
    J Natl Cancer Inst; 2005 Mar; 97(5):401-2; author reply 402. PubMed ID: 15741578
    [No Abstract]   [Full Text] [Related]  

  • 62. NCI-MATCH launch highlights new trial design in precision-medicine era.
    McNeil C
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142446
    [No Abstract]   [Full Text] [Related]  

  • 63. The next generation of targeted therapy trials in colorectal cancer.
    O'Dwyer PJ
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):852-4. PubMed ID: 25674843
    [No Abstract]   [Full Text] [Related]  

  • 64. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
    Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
    J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
    [TBL] [Abstract][Full Text] [Related]  

  • 65. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
    Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
    Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
    Lang N; Weisser A; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
    [No Abstract]   [Full Text] [Related]  

  • 67. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.
    Stover DG; Wagle N
    Curr Oncol Rep; 2015 Apr; 17(4):15. PubMed ID: 25708799
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mutation specific antibodies: tool or dinosaur?
    von Deimling A; Sahm F; Capper D
    Oncotarget; 2012 Sep; 3(9):907-8. PubMed ID: 23006938
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 70. Precision Medicine.
    Khatri VP; Petrelli NJ
    Surg Oncol Clin N Am; 2020 Jan; 29(1):xv-xvi. PubMed ID: 31757318
    [No Abstract]   [Full Text] [Related]  

  • 71. Is Precision Medicine an Oxymoron?
    Eckhardt SG; Lieu C
    JAMA Oncol; 2019 Feb; 5(2):142-143. PubMed ID: 30419105
    [No Abstract]   [Full Text] [Related]  

  • 72. Melanoma: a new landmark in targeted oncology.
    Morère JF
    Target Oncol; 2011 Sep; 6(3):131. PubMed ID: 21858472
    [No Abstract]   [Full Text] [Related]  

  • 73. The pathway ahead in melanoma trials.
    Miller AJ; Markovic SN; Haluska P
    Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
    [No Abstract]   [Full Text] [Related]  

  • 74. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
    Levine O; Devji T; Xie F
    Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
    [No Abstract]   [Full Text] [Related]  

  • 75. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
    Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pairing Cancer Biomarkers to Biomedicine.
    Shin SH; Dong Z
    EBioMedicine; 2017 Nov; 25():1-2. PubMed ID: 29113773
    [No Abstract]   [Full Text] [Related]  

  • 77. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 78. BRAF inhibitors: research accelerates in wake of positive findings.
    Brower V
    J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
    [No Abstract]   [Full Text] [Related]  

  • 79. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 80. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
    O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
    J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.